





Fact Sheet

2009 Q4 Update

Corporate Profile:

Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today – peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, flow diversion, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at www.ev3.net.



* Excludes research collaboration revenue

Analyst Coverage[†]:

Exchange: NASDAQ
Ticker: EVV

CHARLEY JONES
Barrington Research
cjones@brai.com

JOANNE WUENSCH
BMO Capital Markets
joanne.wuensch@bmo.com

JASON MILLS
Canaccord Adams
jason.mills@canaccordadams.com

CHRISTOPHER WARREN
Caris & Company
cwarren@cariscompany.com

CHARLES HAFF
Dougherty Markets
chaff@doughertymarkets.com

MICHAEL WEINSTEIN
JPMorgan
mike.weinstein@jpmorgan.com

JOSH JENNINGS
Jefferies & Company, Inc.
joshjennings@jefferies.com

DAVID LEWIS
Morgan Stanley
david.r.lewis@morganstanley.com

JOSHUA ZABLE
Natixis Bleichroeder, Inc.
joshua.zable@blr.natixis.com

THOMAS GUNDERSON
Piper Jaffray
thomas.j.gunderson@pjc.com

LARRY NEIBOR
R.W. Baird
lneibor@rwbaird.com

TOM KOUCHOUKOS
Stifel Nicolaus & Company
kouchoukost@stifel.com

BETH SENKO
Williams Capital Group
senko@willcap.com

Investor Contact:

JULIE TRACY
Sr. Vice President
Chief Communications Officer
OFFICE 949-680-1375
MOBILE 209-613-6945
jtracy@ev3.net

ev3 Inc.
Corporate World Headquarters
3033 Campus Drive
Plymouth, MN 55441

[†] ev3 is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding ev3's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ev3 or its management. ev3 does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Recent Developments:

February 18, 2010

ev3 Inc. Reports 2009 Fourth Quarter and Full-Year Financial Results and 2010 Guidance

Fourth Quarter Financial Results: ev3's net sales were \$126.8 million in the fourth quarter 2009 versus \$106.1 million in the comparable quarter of 2008. Fourth quarter net product sales totaled \$126.8 million and increased 20% versus the fourth quarter 2008 and 16% on a constant currency basis. Fourth quarter 2008 net sales included \$0.5 million of research collaboration revenues. ev3's net income for the fourth quarter of 2009 increased to \$13.0 million, or \$0.12 per diluted share. ev3's non-GAAP adjusted net income was \$25.7 million, or \$0.23 per diluted share, in the fourth quarter of 2009, compared to net income of \$7.9 million, or \$0.08 per diluted share, in the fourth quarter 2008.

Full-Year Financial Results: ev3's net sales for 2009 increased 6% to \$449.1 million versus \$422.1 million in 2008. For 2009, ev3's non-GAAP adjusted net income was \$66.8 million, or \$0.61 per diluted share compared to net income of \$9.9 million, or \$0.09 per diluted share in the prior year.

Outlook: ev3 expects 2010 net sales to be in the range of \$500 to \$515 million. ev3 expects non-GAAP adjusted earnings per share to be in the range of \$0.78 to \$0.84 per diluted share based on approximately 114.1 million of shares outstanding. ev3's non-GAAP adjusted net earnings per share excludes estimated amortization expense of approximately \$26.0 million, non-cash stock-based compensation of approximately \$14.0 million, and charges relating to the estimated change in fair value of the future contingent consideration associated with the Chestnut acquisition of \$17.2 million.

The company expects first quarter 2010 net sales to be in the range of \$115 to \$118 million. ev3 expects non-GAAP adjusted earnings per share to be in the range of \$0.12 to \$0.15 per diluted share based on approximately 113.4 million shares outstanding. ev3's non-GAAP adjusted net earnings per share excludes estimated amortization expense of approximately \$6.6 million, non-cash stock-based compensation of approximately \$3.2 million and charges relating to the estimated change in fair value of the future contingent consideration associated with the Chestnut acquisition of \$2.5 million.

To access the archived webcast and reconciliations of the non-GAAP financial measures used above to the most comparable U.S. GAAP measures, go to <http://ir.ev3.net>.

December 15, 2009

ev3 Announces Promotion of Two Senior Executives

Pascal Girin Named Executive Vice President and Chief Operating Officer; David Mowry Named Senior Vice President and President, Worldwide Neurovascular

ev3 Inc. (Nasdaq:Evvv) today announced the promotion of two executives effective January 1, 2010. Pascal E.R. Girin has been promoted to the newly created position of executive vice president and chief operating officer, and David Mowry has been promoted to senior vice president and president, worldwide neurovascular.

Robert Palmisano, president and chief executive officer of ev3 Inc., commented, "I'm delighted to announce both of these promotions. Throughout the past six years, Pascal has been a major contributor to the company's growth and success, including the expansion of our international operations and our worldwide neurovascular business to the #2 overall revenue share position. Dave has done an outstanding job of leading our global operations, where he has been instrumental in raising margins, improving manufacturing efficiencies and enhancing our business processes. I'm confident that these promotions will further bolster our ability to capitalize on the growth opportunities within our neurovascular, peripheral vascular and international businesses and to accelerate their market performance."

As chief operating officer, Girin will have global operating responsibility for ev3's peripheral vascular, neurovascular and international businesses. Girin has served as ev3's executive vice president and president, worldwide neurovascular and international since July 2008. Prior to this, Girin served as senior vice president and president of international from August 2007 to July 2008; president of international from July 2005 to August 2007 and European general manager from September 2003 to July 2005. Prior to joining ev3, Girin served in various capacities at BioScience Europe Baxter Healthcare Corporation from September 1998 to August 2003. Girin received an Engineering Education at the French Ecole des Mines.

In his new role, Mowry will have global responsibility for ev3's neurovascular business. Mowry has served as ev3's senior vice president, strategy and corporate operations since July 2008. Prior to this, he served as senior vice president, corporate manufacturing from October 2007 to July 2008 and vice president of operations from November 2006 to October 2007. Prior to ev3, Mowry served as the vice president of operations and logistics at the Zimmer-Spine division of the Zimmer Corporation from February 2004 to November 2006. Prior to Zimmer, he was the president and chief operating officer of Heartstent. Mowry is a graduate of the United States Military Academy in West Point, New York with a degree in Engineering and Mathematics.

November 24, 2009

ev3 Inc. to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009

ev3 presented at the Piper Jaffray Conference on Tuesday, December 1, 2009. To access the webcast, go to <http://ir.ev3.net>.

November 12, 2009

ev3 Inc. to Present at the 2009 Citi Investment Research Small and Mid Cap Conference on November 19, 2009

ev3 presented at the Citi Investment Conference on Thursday, November 19, 2009. To access the webcast, go to <http://ir.ev3.net>.

NEUROVASCULAR | PERIPHERAL VASCULAR

Access · Balloons · Carotid · Embolic Coils · Embolic Protection · Liquid Embolics · Plaque Excision · Procedural Support · Retrieval Devices · Stents

ev3 Corporate

World Headquarters
Peripheral Vascular
3033 Campus Drive
Plymouth, MN 55441
USA
PH +1 763 398 7000
FX +1 763 398 7001
Cust Srv +1 800 716 6700

ev3 Neurovascular

9775 Toledo Way
Irvine, CA 92618
USA
PH +1 949 837 3700
FX +1 949 837 2044

ev3 Europe

International Headquarters
106-108 rue La Boétie
75008 Paris
France
PH +33 156 88 59 10
FX +33 156 88 59 11

www.ev3.net

